ARS Pharmaceuticals Inc (SPRY)
8.17
+0.43
(+5.56%)
USD |
NASDAQ |
Jun 21, 16:00
8.17
0.00 (0.00%)
After-Hours: 16:18
ARS Pharmaceuticals Enterprise Value: 526.34M for June 20, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 20, 2024 | 526.34M |
| June 18, 2024 | 559.28M |
| June 17, 2024 | 591.26M |
| June 14, 2024 | 615.48M |
| June 13, 2024 | 642.61M |
| June 12, 2024 | 658.12M |
| June 11, 2024 | 645.52M |
| June 10, 2024 | 655.21M |
| June 07, 2024 | 630.02M |
| June 06, 2024 | 630.98M |
| June 05, 2024 | 659.08M |
| June 04, 2024 | 642.61M |
| June 03, 2024 | 652.30M |
| May 31, 2024 | 636.80M |
| May 30, 2024 | 639.71M |
| May 29, 2024 | 630.98M |
| May 28, 2024 | 646.49M |
| May 24, 2024 | 646.49M |
| May 23, 2024 | 629.05M |
| May 22, 2024 | 641.64M |
| May 21, 2024 | 631.95M |
| May 20, 2024 | 666.84M |
| May 17, 2024 | 651.33M |
| May 16, 2024 | 658.12M |
| May 15, 2024 | 636.80M |
| Date | Value |
|---|---|
| May 14, 2024 | 646.49M |
| May 13, 2024 | 637.77M |
| May 10, 2024 | 623.23M |
| May 09, 2024 | 629.05M |
| May 08, 2024 | 654.24M |
| May 07, 2024 | 693.97M |
| May 06, 2024 | 692.03M |
| May 03, 2024 | 721.09M |
| May 02, 2024 | 692.99M |
| May 01, 2024 | 680.39M |
| April 30, 2024 | 619.35M |
| April 29, 2024 | 609.66M |
| April 26, 2024 | 585.44M |
| April 25, 2024 | 560.24M |
| April 24, 2024 | 576.72M |
| April 23, 2024 | 597.25M |
| April 22, 2024 | 569.24M |
| April 19, 2024 | 594.35M |
| April 18, 2024 | 591.45M |
| April 17, 2024 | 651.33M |
| April 16, 2024 | 662.92M |
| April 15, 2024 | 668.71M |
| April 12, 2024 | 647.47M |
| April 11, 2024 | 668.71M |
| April 10, 2024 | 671.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
26.85M
Minimum
Sep 20 2023
808.83M
Maximum
Dec 14 2022
432.00M
Average
419.64M
Median
Aug 22 2023
Enterprise Value Benchmarks
| KalVista Pharmaceuticals Inc | 396.50M |
| Phathom Pharmaceuticals Inc | 517.51M |
| Vera Therapeutics Inc | 1.597B |
| Nuvalent Inc | 4.372B |
| CEL-SCI Corp | 61.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.29M |
| Total Expenses (Quarterly) | 13.19M |
| EPS Diluted (Quarterly) | -0.11 |
| Earnings Yield | -6.36% |
| Normalized Earnings Yield | -6.901 |